Genzyme Completes Acquisition Of Ilex, Awaits Clolar Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme closes $1 bil. deal the day after receiving Federal Trade Commission approval. Clolar could be Genzyme's first direct presence in oncology therapeutic market; FDA's user fee deadline is Dec. 30.
You may also be interested in...
Campath Antitrust Order Focuses On Off-Label Use In Organ Transplant Market
Schering AG will take over sole rights for development and marketing of Campath as acute therapy for solid organ transplant rejection as a result of the Genzyme/Ilex merger
Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.
Genzyme Eyeing Fourth Quarter Close For Ilex Merger
Genzyme expects its proposed merger with Ilex to close in the fourth quarter, Genzyme CEO Henri Termeer said